Phase 3 TRIUMPH-1 • Eli Lilly 2026

Retatrutide Before and After: What the Clinical Data Shows

📄 7 PubMed citations🧪 Phase 3 trial

Last updated: June 2026

Retatrutide's Phase 3 TRIUMPH-1 trial showed participants lost an average of 25.0% of body weight at the highest dose (12mg) over 80 weeks, vs. 3.9% with placebo — compared with 24.2% over 48 weeks reported in the earlier Phase 2 trial.

Source note: TRIUMPH-1 is now published in NEJM (Jastreboff et al. 2026, PMID 42814954); its abstract reports a 25.0% mean weight loss at 12 mg over 80 weeks vs. 3.9% with placebo (treatment-regimen estimand). The 48-week Phase 2 comparison (24.2%) is peer-reviewed (Jastreboff et al., NEJM 2023, PMID 37366315).

Real weight loss results from retatrutide (LY3437943) — the triple-agonist that produced a 25.0% mean body weight loss at 12 mg over 80 weeks in Phase 3 TRIUMPH-1, building on its 24.2% Phase 2 result at 48 weeks.

Where to buy · affiliate link
Retatrutide 10 mglisted as GLP-3 RT at Veratis$80

Code HIGHPEPTIDES takes 15% off at checkout: $68

Third-party COA on every lotIn stockShips in the lower 48, $15 standard
Buy retatrutide at Veratis →

Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.

25.0%
Mean Weight Loss, 12 mg (TRIUMPH-1)
80 wk
Study Duration
2339
Participants

Build your own printable peptide tracker

A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

Retatrutide Weight Loss by Dose

Percent change in body weight at 48 weeks across all dose groups. Data from the Phase 2 trial (NCT04881760).

Placebo
−2.1%
1 mg
−8.7%
4 mg (combined)
−17.1%
8 mg
−22.8%
12 mg
−24.2%

How Fast Does Retatrutide Work?

Percent body weight change at key timepoints (24 and 48 weeks) across dose groups. These are the reported timepoints from the Phase 2 trial.

At 24 Weeks
Placebo
−1.6%
1 mg
−7.2%
4 mg (combined)
−12.9%
8 mg
−17.3%
12 mg
−17.5%
At 48 Weeks (Final)
Placebo
−2.1%
1 mg
−8.7%
4 mg (combined)
−17.1%
8 mg
−22.8%
12 mg
−24.2%

Note: 24- and 48-week values are least-squares means from the published Phase 2 abstract (Jastreboff et al. 2023, PMID 37366315); the 4 mg and 8 mg values are combined dose groups.

What Retatrutide Results Look Like in Real Weight

Based on trial averages applied to an example starting weight of 220 lbs (100 kg). Individual results vary.

Dose Group % Lost at 24 wk Weight at 24 wk % Lost at 48 wk Weight at 48 wk Total lbs Lost
Placebo −1.6% 216.5 lbs −2.1% 215.4 lbs 4.6 lbs
1 mg −7.2% 204.2 lbs −8.7% 200.9 lbs 19.1 lbs
4 mg (combined) −12.9% 191.6 lbs −17.1% 182.4 lbs 37.6 lbs
8 mg −17.3% 181.9 lbs −22.8% 169.8 lbs 50.2 lbs
12 mg −17.5% 181.5 lbs −24.2% 166.8 lbs 53.2 lbs

Starting weight: 220 lbs (100 kg). "Weight at X wk" = 220 × (1 − % lost). These are averages; individual results vary significantly.

Retatrutide vs. Tirzepatide vs. Semaglutide

Peak weight loss across three landmark clinical trials. Different study durations (see caveat below).

Tirzepatide
15 mg weekly
−20.9%
72 weeks
SURMOUNT-1, Jastreboff et al., NEJM 2022 (PMID 35658024)
Semaglutide
2.4 mg weekly
−14.9%
68 weeks
STEP 1, Wilding et al., NEJM 2021 (PMID 33567185)
⚠️ Cross-trial comparison caveat: These results come from different trials with different durations, patient populations, and study designs. Retatrutide's result is from the Phase 3 TRIUMPH-1 trial (80 weeks), while tirzepatide and semaglutide data are from their Phase 3 trials (72 and 68 weeks). Direct comparison requires head-to-head studies, which have not yet been conducted.

Fat Loss vs. Lean Mass

The published Phase 2 and Phase 3 abstracts cited on this page do not report fat-mass vs. lean-mass breakdowns, so we do not quote a fat-to-lean ratio here.

Resistance training during weight loss can help preserve lean mass.

Most Common Adverse Events

Gastrointestinal events were the most common adverse events in the Phase 2 trial (PMID 37366315). GI events were dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose (2 mg vs. 4 mg).

Retatrutide Weight Loss Timeline

The phase 2 trial reported weight change only at 24 and 48 weeks (PMID 37366315); the early phases below describe the dosing schedule, not measured week-by-week results.

Week 1–4
Starting Dose
In phase 2, the higher-dose arms started at 2 mg or 4 mg before stepping up to their target dose. GI events were the most common adverse events and were partially mitigated by the lower 2 mg starting dose (PMID 37366315); the abstract does not report when they occurred.
Week 4–12
Dose Escalation
Doses continue stepping up toward the assigned maintenance dose. The cited abstracts report no weight-loss figures for this window.
Week 12–24
First Reported Result
12 mg group at −17.5% by week 24 (least-squares mean, PMID 37366315), the trial's primary endpoint.
Week 24–48
Continued Progress
Weight loss continues at a slower average pace than in the first 24 weeks: the 12 mg group went from −17.5% at 24 weeks to −24.2% at 48 weeks (PMID 37366315). Phase 3 TRIUMPH-1 extended this to 80 weeks, with a 25.0% mean loss at 12 mg (PMID 42814954).

Retatrutide Before and After — The Bottom Line

What We Know

  • The 12 mg dose produced 24.2% mean body weight loss at 48 weeks in Phase 2; Phase 3 TRIUMPH-1 reported 25.0% mean loss at 12 mg over 80 weeks (PMID 42814954)
  • Clear dose-response: higher doses produced more weight loss
  • Weight was still declining at 48 weeks (the study hadn't plateaued)
  • GI side effects are the most common adverse events, dose-related and mostly mild-to-moderate, and were partly reduced by a lower starting dose (PMID 37366315)
  • Triple-agonist mechanism (GIP + GLP-1 + Glucagon) differentiates it from existing drugs
  • Phase 3 TRIUMPH-1 has reported (25.0% mean at 12 mg over 80 weeks); the broader TRIUMPH program continues for more definitive data

What We Don't Know

  • Long-term safety beyond the 80-week TRIUMPH-1 readout is still being established — the full Phase 3 package is ongoing
  • What happens after discontinuation (weight regain is expected based on other GLP-1 drugs)
  • Cardiovascular outcomes data (no CVOT completed yet)
  • How it compares head-to-head vs tirzepatide or semaglutide
  • Optimal dosing for balancing weight loss against GI side effects
  • Effects in specific populations such as older adults
  • FDA approval timeline: still investigational, not approved for any indication

Essential Tools for Weight Loss Tracking

Tracking your weight, body composition, and meals is critical for anyone on a weight loss journey.

Affiliate links support HighPeptides at no extra cost.

Mental Clarity, Cognition & Inflammation

Beyond fat loss, there is interest in whether retatrutide affects cognition and inflammation. Here is the receptor-level mechanism, and exactly where the evidence stops.

Cognition. In the phase 2b ELAD trial, liraglutide did not change the primary endpoint of cerebral glucose metabolism in Alzheimer's patients, but a secondary executive-function score (ADAS-Exec) favored liraglutide over placebo (Edison 2026, PMID 41326666), and in Parkinson's the Exenatide-PD trial found exenatide preserved off-medication motor function (Athauda 2017, PMID 28781108). Retatrutide adds GIP and glucagon receptor activity (GLP-1/GIP dual agonists were neuroprotective in preclinical models, PMID 29402504; no such data are cited here for glucagon receptor activity), but whether retatrutide affects cognition in people is untested: no retatrutide-specific cognition trial exists yet.

Inflammation. In preclinical models, GLP-1 / GIP dual agonists reduced neuroinflammation and oxidative stress and protected synaptic numbers and synaptic activity (Hölscher review, PMID 29402504). Systemically, retatrutide produced a least-squares mean 24.2% reduction in body weight at 48 weeks in the highest-dose (12 mg) arm of the phase 2 obesity trial (Jastreboff 2023, PMID 37366315), but that trial's abstract reports no fat-mass or inflammatory-marker results, so any anti-inflammatory effect in people is unmeasured.

What we don't know. No retatrutide-specific trial has yet powered a cognition score or an inflammatory marker (CRP, IL-6) as a primary endpoint. The cognition and neuroinflammation findings above are GLP-1 class effects and preclinical mechanism — limited and indirect (ELAD missed its primary endpoint), not retatrutide-specific proof.

→ Full deep-dive: Retatrutide Beyond Weight Loss

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.


Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)
Research Chemical Vendor

Research-Grade Peptides

Sold for research use only — not FDA-approved for human use, with no guarantee of identity, purity, or dose. Ask for batch-specific certificates of analysis.

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is an investigational drug not approved by the FDA. "Before and after" data represents clinical trial averages — individual results vary significantly. Always consult with a qualified healthcare provider. Data sourced from Jastreboff et al., N Engl J Med 2026 (Phase 3 TRIUMPH-1, PMID 42814954; ClinicalTrials.gov: NCT05929066) and Jastreboff et al., N Engl J Med 2023; 389:514-526 (Phase 2; ClinicalTrials.gov: NCT04881760).

Frequently Asked Questions

What does retatrutide weight loss look like?

Phase 3 TRIUMPH-1 data shows participants on retatrutide 12mg lost an average of 25.0% of body weight over 80 weeks (vs. 3.9% with placebo; PMID 42814954), compared with 24.2% over 48 weeks reported in the earlier Phase 2 trial.

How fast do you lose weight on retatrutide?

In the Phase 2 trial, weight loss continued throughout the 48-week study period.

Is retatrutide better than semaglutide?

In separate trials, retatrutide produced larger average weight loss (25.0% at 80 weeks in Phase 3 TRIUMPH-1; 24.2% at 48 weeks in Phase 2) than semaglutide (14.9% at 68 weeks in STEP 1, PMID 33567185), but no head-to-head statistical comparison exists. However, head-to-head trials have not been conducted, and retatrutide is not yet FDA-approved.

Buyer Q&A

Answer-first buying questions. Educational purposes only. Not medical advice.

Where can I buy retatrutide?

Retatrutide is an investigational drug — as of 2026 it is still in clinical trials and is not FDA-approved or commercially available by prescription. Any retatrutide sold online is an unapproved research chemical with no human-use authorization and no guarantee of identity, purity, or dose. The only sanctioned way to access it is enrollment in a registered clinical trial.

Is Swiss Chems a legit place to source research peptides?

Swiss Chems is a research-chemical vendor and a HighPeptides affiliate partner (we may earn a commission). We have not independently verified its products, and nothing sold as a research chemical is FDA-approved for human use. Insist on batch-specific COAs and treat every vendor claim critically.

What should I look for in a peptide vendor?

Demand batch-specific third-party COAs (HPLC purity plus mass-spec identity) you can download, transparent sourcing, and a vendor that makes no human-dosing or medical claims. Third-party testing tells you what is in the vial — it does not make an unapproved compound safe or legal to use. This is educational information, not medical advice.
Get the Guide: $19 (normally $29) → Links to our guide (educational, not medical advice.)
📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.

Anecdotal — Early Signal, Not Studied

What People Report

Aggregated, unverified reports from public X posts. This is not clinical evidence — see the disclaimer below. We report what people say in aggregate; we do not endorse any claim.

~25 independent users report weight loss / fat loss
▲ positive
27 posts · Jun 5 – Jul 12 · individual reports, not a controlled study
“Fitness Update: End of 3 months of Bulking. Starting a 3 month cut tomorrow, my last cut of 2026. I lost about 50 pounds from January 2025 till the end of March 2026 with a 13 month straight cut aided by Retatrutide and Tirzepatide. Counted calories and ran a deficit and lifted weights the whole time. My body needed a…”
@ClintFiore · Jun 27 · 179 likes on X ↗
“90 days ago, I decided to get my health back. As a startup founder, stress, lack of sleep, and comfort food quickly creep up on your health insanely fast. I went all in: daily workout, intermittent fasting, protein and carbs counting, no processed food, retatrutide, 8hrs sleep min, 15k steps, 0 alcohol. 90 days later…”
@nassyweazy · Jun 26 · 111 likes on X ↗
“🧪 Phase 3 Retatrutide Trial — Day 90 📦 Package secured. Latest readings: • Weight: 332.9 → 299.6 lbs (-33.3) • Waist: 51.2” → 47.6” (-3.6”) • Blood pressure: 152/93 → 135/80 Trial notes: • First 8 weeks: 2mg • Currently: Week 5 on 4mg Clinic day today. First full blood panel since Day 1. They still take blood every…”
@RetaDiary · Jun 30 · 94 likes on X ↗
“It's true. I took Victoza, which was the first generation daily injection for 5 years, for prediabetes. I stopped taking it & the weight came back, despite eating & exercising the same as on Victoza. Then I took Ozempic & actually gained another 20 lbs. Now I'm on retatrutide & plan on taking it forever. I have had no…”
@Melania12gG · Jul 7 · 15 likes on X ↗
“@NocturnalNelly 100% agree. Ordered some Retatrutide 30 mg from the Chinese at ~$22/vial. Worked as advertised and I'm down over 20 lbs so far. Also got so ghk-cu even cheaper, about $9/vial. So far so good.”
@jeremystandifor · Jul 3 · 7 likes on X ↗
These are unverified individual reports from public social media — not clinical evidence, and not collected under controlled trial conditions. Individual reports may reflect placebo, bias, or misattribution. Educational only, not medical advice.